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Abstract 
Background: Little is known about the impact of rare diseases on inpatient outcomes.
Objective: To compare outcomes of inpatients with 0, 1, or > 1 rare disease. A catalogue of 628 ICD-10 coded rare 
diseases was applied to count rare diseases.
Design: Retrospective, cross-sectional study.
Subjects: 165,908 inpatients, Swiss teaching hospital.
Main measures: Primary outcome: in-hospital mortality. Secondary outcomes: length of stay (LOS), intensive care 
unit (ICU) admissions, ICU LOS, and 30-day readmissions. Associations with single and combined rare diseases were 
analyzed by multivariable regression.
Key results: Patients with 1 rare disease were at increased risk of in-hospital death (odds ratio [OR]: 1.80; 95% confi-
dence interval [CI]: 1.67, 1.95), combinations of rare diseases showed stronger associations (OR 2.78; 95% CI 2.39, 3.23). 
Females with 1 rare disease had an OR of 1.69 (95% CI 1.50, 1.91) for in-hospital death, an OR of 2.99 (95% CI 2.36, 3.79) 
if they had a combination of rare diseases. Males had an OR of 1.85 (95% CI 1.68, 2.04) and 2.61 (95% CI 2.15, 3.16), 
respectively. Rare diseases were associated with longer LOS (for 1 and > 1 rare diseases: increase by 28 and 49%), ICU 
admissions (for 1 and > 1: OR 1.64 [95% CI 1.57, 1.71] and 2.23 [95% CI 2.01, 2.48]), longer ICU LOS (for 1 and > 1 rare 
diseases: increase by 14 and 40%), and 30-day readmissions (for 1 and > 1: OR 1.57 [95% CI 1.47, 1.68] and 1.64 [95% CI 
1.37, 1.96]).
Conclusions: Rare diseases are independently associated with worse inpatient outcomes. This might be the first 
study suggesting even stronger associations of combined rare diseases with in-hospital deaths, increased LOS, ICU 
admissions, increased ICU LOS, and 30-day readmissions.
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Introduction
Rare diseases are a diverse group of diseases with a 
low prevalence. The defined prevalence thresholds 
of rare diseases vary across references from 5 to 76 
cases/100,000 people [1], that is, rare diseases affect a 
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small fraction of the population. Respective estimates 
range from 3.5–6.2% [2, 3] for the general popula-
tion [4, 5].
From an epidemiological and clinical viewpoint, rare 
diseases share some characteristics and challenges [2] 
that are fundamentally different from those of more 
common diseases [6]. Patients with rare diseases are 
geographically widely dispersed, there is a scarcity of 
clinical expertise and expert centers [6], the patients 
frequently face misdiagnosis and diagnostic delays [7], 
and many rare diseases are incurable to date [8].
The fraction of studies into general health indicators 
and clinical outcomes (i.e., mortality or health-care 
utilization) of rare diseases in comparison with more 
frequent conditions is rather small [9]. Some research 
groups found a disparity between the few patients with 
rare diseases and their high combined healthcare costs 
[10, 11]. In general, however, little is known about 
the clinical impact of rare diseases among inpatients. 
To our knowledge, no study investigated the effect of 
combinations of rare diseases on clinical outcomes in 
the inpatient setting.
Therefore, we examined the impact of the presence 
of single rare diseases and combinations of rare dis-
eases on inpatient outcomes, focusing on generalizable 
clinical end points and healthcare utilization. In this 
context, we studied associations of rare diseases with 
(i) in-hospital mortality, (ii) increased length of stay 
(LOS), (iii) intensive care unit (ICU) admissions, (iv) 
increased ICU LOS, and (v) 30-day readmissions.
Methods
Design and study period
We conducted a retrospective, cross-sectional study 
of routinely prospectively collected electronic health 
record data of all patients discharged from a Swiss 
teaching hospital between August  1st, 2009 and August 
 31st, 2017. The present investigation used completely 
anonymous data and conformed with the local law and 
the ethical review and research policies. Our study 
adhered to the STrengthening the Reporting of OBser-
vational studies in Epidemiology (STROBE) guidelines 
[12].
Setting
The study was performed at a Swiss tertiary care aca-
demic medical center with approximately 850 beds and 
over 35,000 admissions per year. It covers all clinical 
specialties except orthopedic surgery and pediatrics. 
Our dataset was derived from a hospital caring for 
adult patients, and we therefore measured the impact of 
rare diseases on adult inpatient outcomes, independent 
of when in the patient’s life the rare disease originated.
Participants with their stays and diagnoses
As shown in Fig.  1, we included all adult patients 
(aged ≥ 18) who had at least one hospital stay during 
the study period, and only stays with at least one diag-
nosis were considered.
Two thirds of the patients (110,880patients) stayed 
once in the institution during the study period, whereas 
the remaining third (55,028patients) had two or more 
stays. In respect of the latter group of inpatients who 
stayed multiple times, the analyzed stays were ran-
domly selected to avoid selection bias and to prevent 
prevalence errors due to patients with rare diseases 
who stayed multiple times. Thereby we ended up ana-
lyzing a total of 165,908 patients with one stay each.
The physicians in charge of the patients assigned 
and updated all diagnoses over the course of the hos-
pital stay. After discharge of the patients, professional 
coders assigned ICD-10 codes to each diagnosis (ICD: 
International Classification of Diseases, WHO, Geneva, 
Switzerland).
Main outcomes and measures
The primary outcome was the association of rare dis-
eases with in-hospital mortality. All 165,908 patient 
stays were considered in this analysis.
We analyzed four secondary outcomes. The first one 
addressed was the association of rare diseases with ICU 
admissions. For all remaining secondary outcomes, 
stays during which the patient died were excluded. 
Additional secondary outcomes analyzed were LOS 
(i.e. LOS in the hospital if not otherwise specified), the 
LOS in the ICU, and readmissions within 30 days after 
patient discharge.
For the outcome LOS in the ICU, only stays that fea-
tured ICU admissions were considered. For the outcome 
30-day readmission, only stays with complete informa-
tion in respect of the number of previous stays within 
the past two years before admission as well as complete 
information on potential readmission events were con-
sidered [13].
Exposure
The exposure of interest was the presence of either a 
single rare disease or a combination of rare diseases. 
To identify patients with at least one rare disease and 
to count the total number or rare diseases per patient, 
we assembled a broad catalogue of ICD-10 coded rare 
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diseases. The sources, developmental steps and iterative 
improvements of that catalogue is detailed below.
Catalogue of ICD‑10 coded rare diseases
The Orphanet/Orphadata websites provide a catalogue 
with more than 10,000 rare diseases, of which 8,015 are 
mapped to a total of 2,075 distinct ICD-10 codes [14–17]. 
Of those ICD-10 codes, the most frequently found in 
our study population was E11.9, supposedly coding for 
Maturity Onset Diabetes of the Young (MODY) accord-
ing to Orphadata. In fact, however, E11.9 officially codes 
for Type 2 diabetes mellitus without complications, which 
is not rare. We therefore checked whether Orphadata’s 
descriptions of their ICD-10 codes were equivalent to 
the official WHO descriptions of the respective ICD-10 
codes.
All confirmed ICD-10 codes were then added to the 
previously published catalogue by Walker et  al. [11]. 
Thereby, we were able to expand the latter by 160 rare 
diseases, among them 79 rare infectious diseases that 
were originally excluded. Further steps to improve the 
new catalogue were performed. Codes were truncated to 
three or four digits if possible, e.g. Q05.0 to Q05.9 were 
covered by Q05 Spina bifida and therefore replaced by 
that single code.
All codes in the new catalogue were considered as 
“wildcards” that can fit in longer, more specific ICD-10 
codes found among our inpatients, but not vice versa: On 
the one hand, the ICD-10 codes of our study population’s 
diagnoses were truncated to match the catalogue codes 
(e.g. if a patient had the code D57.1 Sickle-cell anaemia 
without crisis, that code would be truncated to D57 in 
Fig. 1 Patient flow diagram and performed outcome analyses
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order to match the catalogue code D57 Sickle-cell disor-
ders, and the patient would thus be considered as having 
a rare disease). On the other hand, the catalogue codes 
were never truncated to match the study population’s 
ICD-10 codes (e.g. if a patient had the code A92 Other 
mosquito-borne viral fevers, the catalogue code A92.4 Rift 
Valley fever would not be truncated to A92, hence the 
patient’s code would not match and the patient would not 
be considered as suffering from Rift Valley fever).
Finally, with a commonly used threshold for the gen-
eral population [1], we conservatively double-checked in 
detail all codes with a prevalence among our inpatients 
of ≥ 1/2,000, which triggered further fine-tuning, e.g. the 
codes subsumed under Cranial neuralgia in the Walker 
catalogue (G50 to G53) received their official WHO 
descriptions instead.
Of a total of 628 distinct ICD-10 coded rare diseases in 
our new catalogue (Additional file  1:  available with this 
publication as online supplementary material), 437 (70%) 
were found at least once in the study population. The 
patients were grouped into three categories based on the 
number of rare diseases they had (0, 1, > 1).
Co‑variables
All regression models were adjusted for age group, sex, 
the calendar year of hospital discharge, and diagnosis 
count of non-rare diseases [18] to control for disease bur-
den. The readmission analyses controlled for the number 
of previous stays in the past two years and for the LOS, in 
addition to the co-variables mentioned.
Statistical analysis
For descriptive analyses, categorical variables are pre-
sented as counts and percentages. Continuous variables 
with non-normal distributions are presented as medians 
and interquartile ranges. For the ICU LOS, due to the 
usually very low number of days in the ICU, we addition-
ally present the mean (with standard deviation). Chi-
squared tests were used to compare categorical variables, 
Kruskal–Wallis tests to compare continuous variables 
between patient groups.
Associations of single or combined rare diseases with 
clinical outcomes were analyzed by means of multivari-
able logistic regression models for in-hospital mortality, 
ICU admissions, and 30-day readmissions, and multivari-
able linear regression models for LOS, and LOS in the 
ICU.
We used the natural logarithm to transform the skewed 
outcome variables LOS and LOS in the ICU, described 
in more detail elsewhere [13]. The estimated coeffi-
cients were back-transformed by exponentiation of the 
coefficients. The back-transformed values can be inter-
preted as percentage increases or decreases.
Analyses were performed with R, version 4.0.2 (R 
Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 165,908 patients were included in our study 
(Fig. 1.). Table 1 illustrates the baseline characteristics of 
the patients stratified by their number of rare diseases. 
146,804 patients had no rare diseases, whereas 19,104 
(11.5%) had one or a combination of rare diseases.
Primary end point
The unadjusted logistic regression model indicated an 
increased in-hospital mortality associated with the pres-
ence of a single rare disease (odds ratio [OR] 3.04; 95% 
confidence interval [CI]: 2.83 to 3.26), and with the pres-
ence of combined rare diseases (OR 6.56; 95% CI 5.74 
to 7.50). After adjusting for co-variables, the multivari-
able logistic regression model showed that rare diseases 
were independently associated with in-hospital mortal-
ity (Table 2). Of note, patients with combinations of rare 
diseases showed substantially stronger associations with 
in-hospital death: Compared to patients without any 
rare diseases, patients with combined rare diseases had 
an OR of 2.78 (95% CI 2.39 to 3.23) for in-hospital death. 
Adjusted models for a female subgroup resulted in an 
increased OR of 1.69 (95% CI 1.50 to 1.91) for in-hospital 
death if they had a single rare disease, and an OR of 2.99 
(95% CI 2.36 to 3.79) if they had a combination of rare 
diseases (not shown). Adjusted models for a male sub-
group resulted in OR of 1.85 (95% CI 1.68 to 2.04) and 
2.61 (95% CI 2.15 to 3.16), respectively (not shown).
We ran three sensitivity analyses, (i) to check whether 
our results would substantially differ when we adjusted 
for the number of stays each patient had during the study 
period. This resulted in OR of 1.86 (95% CI 1.72 to 2.01) 
and 2.98 (95% CI 2.55 to 3.47) for 1 and > 1 rare disease, 
respectively (not shown). (ii) To assess the influence of 
concomitant non-rare conditions, we included an inter-
action term “number of rare diseases” * “number of non-
rare diseases”. This resulted in OR of 2.10 (95% CI 1.80 
to 2.46) and 4.30 (95% CI 3.05 to 6.07), respectively (not 
shown). And (iii) to investigate whether the specialty of 
the clinical unit where patients received treatment con-
founded our findings, we included an interaction term 
“number of rare diseases” * “group of clinical units” (i.e. 
“internal medicine and related units” vs. “surgical units” 
vs. “other units”). This resulted in OR of 1.77 (95% CI 
1.46 to 2.14) and 2.74 (95% CI 1.80 to 4.18), respectively 
(not shown).
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Secondary end points
Rare diseases were statistically significantly associated 
with ICU admissions, longer LOS, longer ICU LOS 
(Table 2) and 30-day readmissions (Table 3). The associa-
tions with ICU admissions, longer LOS, and longer ICU 
LOS were substantially stronger among patients with 
combinations of rare diseases.
Discussion
This study suggests that the presence of rare diseases is 
independently associated with worse inpatient outcomes, 
that is, in-hospital mortality, ICU admissions, LOS, ICU 
LOS, and 30-day readmissions. These findings persist 
after controlling for the influence of several potentially 
confounding factors, including demographics and burden 
Table 1 The baseline characteristics of the patients stratified by their number of rare diseases
All p-values < 0.001
Number of rare diseases per patient 0 1  > 1
Number of patients per group 146,804 17,051 2053
Demographics
Age groups (%)
 18–34 36,084 (24.6) 2280 (13.4) 291 (14.2)
 35–49 32,924 (22.4) 2905 (17.0) 382 (18.6)
 50–64 31,883 (21.7) 4679 (27.4) 593 (28.9)
 65–79 31,417 (21.4) 5160 (30.3) 615 (30.0)
 80 and older 14,496 (9.9) 2027 (11.9) 172 (8.4)
Sex = M (%) 67,557 (46.0) 9437 (55.3) 1179 (57.4)
Diagnosis count, excluding rare diseases (median [IQR]) 4.00 [2.00, 7.00] 5.00 [3.00, 9.00] 8.00 [4.00, 13.00]
Rare diseases
Certain infectious and parasitic diseases (%) 0 (0.0) 516 (3.0) 192 (9.4)
Neoplasms (%) 0 (0.0) 3035 (17.8) 590 (28.7)
Diseases of the blood and blood-forming organs and certain disorders involving the immune 
mechanism (%)
0 (0.0) 609 (3.6) 159 (7.7)
Endocrine nutritional and metabolic diseases (%) 0 (0.0) 1772 (10.4) 467 (22.7)
Mental and behavioural disorders (%) 0 (0.0) 22 (0.1) 6 (0.3)
Diseases of the nervous system (%) 0 (0.0) 3357 (19.7) 574 (28.0)
Diseases of the eye and adnexa (%) 0 (0.0) 401 (2.4) 49 (2.4)
Diseases of the ear and mastoid process (%) 0 (0.0) 169 (1.0) 30 (1.5)
Diseases of the circulatory system (%) 0 (0.0) 1551 (9.1) 393 (19.1)
Diseases of the respiratory system (%) 0 (0.0) 210 (1.2) 57 (2.8)
Diseases of the digestive system (%) 0 (0.0) 655 (3.8) 234 (11.4)
Diseases of the skin and subcutaneous tissue (%) 0 (0.0) 307 (1.8) 56 (2.7)
Diseases of the musculoskeletal system and connective tissue (%) 0 (0.0) 1659 (9.7) 280 (13.6)
Diseases of the genitourinary system (%) 0 (0.0) 78 (0.5) 4 (0.2)
Pregnancy childbirth and the puerperium (%) 0 (0.0) 167 (1.0) 6 (0.3)
Congenital malformations, deformations and chromosomal abnormalities (%) 0 (0.0) 1958 (11.5) 460 (22.4)
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (%) 0 (0.0) 585 (3.4) 162 (7.9)
Outcomes
Number of patients who died in hospital (%) 3202 (2.2) 1082 (6.3) 262 (12.8)
30-day readmission (%)
 No 137,918 (93.9) 15,364 (90.1) 1819 (88.6)
 Unknown 1768 (1.2) 215 (1.3) 29 (1.4)
 Yes 7118 (4.8) 1472 (8.6) 205 (10.0)
Length of stay in days (median [IQR]) 5.00 [3.00, 8.00] 7.00 [4.00, 14.00] 11.00 [5.00, 20.00]
ICU admissions (%) 16,178 (11.0) 3987 (23.4) 763 (37.2)
Total time spent in ICUs in days (median [IQR]) 0.00 [0.00, 0.00] 0.00 [0.00, 0.00] 0.00 [0.00, 2.00]
Total time spent in ICUs in days (mean (SD)) 0.44 (2.70) 1.45 (5.63) 3.59 (9.39)
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of disease [18]. While we observed those associations in 
patients with a single rare disease, our study might be 
the first suggesting substantially stronger associations of 
combined rare diseases with worsening of some inpatient 
outcomes, especially in-hospital mortality and ICU LOS.
Rare diseases have been found to account for a greater 
average length of stay than what the general inpatient 
population shows [10, 11]. Specific rare diseases, like 
muscular dystrophies, spina bifida and fragile X syn-
drome were associated with a higher 30-day all-cause 
readmission rate [19]. Rare diseases seem to be associ-
ated with significant economic burden  [20] and a dis-
parity was found regarding healthcare costs and the 
proportion of the population with rare diseases [10, 11].
To our knowledge, this is the first study on inpatients 
with rare diseases that analyzes associations with five 
important clinical outcomes. Moreover, we paid spe-
cial attention to patient groups with more than one rare 
disease, thereby investigating the possibility of dose–
response relationships between the number of rare dis-
eases and clinical outcomes. The only outcome not 
necessarily suggesting such a dose–response relation-
ship was 30-day readmissions. Whether a rare disease is 
present seems to influence clinical outcomes of the inpa-
tients and in turn hospital resource utilization, which is 
of significance for public health and the healthcare sys-
tem as a whole.
On the one hand, we considered a broad catalogue of 
ICD-10 coded rare diseases. On the other hand, our pro-
portion of inpatients with rare diseases might be higher 
than it would be in other Swiss institutions, because our 
cohort was derived from a tertiary care academic medical 
center with highly specialized clinical units and experts 
providing highly specialized care. Many patients are 
Table 2 Multivariable regression models for in-hospital mortality, ICU admissions, LOS, and ICU LOS
ICU: intensive care unit, LOS: length of stay
Variable In‑hospital death ICU admission LOS ICU LOS
OR (95% CI) OR (95% CI) Exp(B) (95% CI) Exp(B) (95% CI)
Patients without rare diseases Ref Ref Ref Ref
Patients with one rare disease 1.80 (1.67,1.95) 1.64 (1.57,1.71) 1.28 (1.27,1.29) 1.14 (1.10,1.18)
Patients with more than one rare disease 2.78 (2.39,3.23) 2.23 (2.01,2.48) 1.49 (1.45,1.54) 1.40 (1.30,1.51)
Patients aged 18–34 Ref Ref Ref Ref
Patients aged 35–49 2.05 (1.72,2.45) 1.49 (1.40,1.58) 1.07 (1.06,1.08) 1.03 (0.98,1.09)
Patients aged 50–64 3.76 (3.20,4.41) 2.18 (2.06,2.30) 1.10 (1.09,1.11) 0.97 (0.93,1.01)
Patients aged 65–79 4.46 (3.81,5.23) 2.03 (1.92,2.14) 1.04 (1.03,1.05) 0.85 (0.82,0.89)
Patients aged 80 and older 7.88 (6.72,9.25) 1.16 (1.09,1.25) 0.97 (0.95,0.98) 0.71 (0.67,0.75)
Female sex Ref Ref Ref Ref
Male sex 1.19 (1.11,1.26) 1.71 (1.66,1.77) 0.95 (0.94,0.95) 0.97 (0.94,0.99)
Number of diagnoses (excluding rare diseases),
per additional diagnosis 1.20 (1.19,1.20) 1.20 (1.20,1.21) 1.10 (1.10,1.10) 1.12 (1.12,1.12)
Year discharged,
per additional year 0.91 (0.90,0.92) 0.94 (0.93,0.94) 0.99 (0.99,0.99) 0.95 (0.94,0.95)





Patients without rare diseases ref
Patients with one rare disease 1.57 (1.47,1.68)
Patients with more than one rare disease 1.64 (1.37,1.96)
Patients aged 18–34 ref
Patients aged 35–49 1.11 (1.02,1.21)
Patients aged 50–64 1.33 (1.23,1.44)
Patients aged 65–79 1.40 (1.29,1.52)
Patients aged 80 and older 1.31 (1.18,1.44)
Female sex ref
Male sex 1.26 (1.20,1.33)
Number of diagnoses (excluding rare diseases),
per additional diagnosis 1.02 (1.02,1.03)
Year discharged,
per additional year 0.99 (0.98,1.01)
No previous stays (within prior two years) ref
1 previous stay (within prior two years) 1.87 (1.74,2.00)
2 previous stays (within prior two years) 2.80 (2.53,3.11)
3 or more previous stays (within prior two years) 5.86 (5.33,6.44)
Length of stay,
per additional day 1.01 (1.01,1.01)
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referred to our institution due to the level of specializa-
tion also in respect of diagnostic competencies.
The limitations of our study should be taken into 
account in interpreting our results. A single center study 
like ours provides a lower generalizability of the results 
and conclusions than multi-center studies. However, 
we included all patients with at least one diagnosis, that 
is, a large, comprehensive and medically diverse inpa-
tient cohort, which may have improved generalizabil-
ity. Further, ICD codes are mainly added to the health 
records for billing and administrative purposes but not 
for research [21], and we cannot rule out that some rare 
diseases that are predominantly treated in outpatient 
settings might have been missed in our study. Also, rare 
diseases are underrepresented in healthcare coding sys-
tems and only a modest fraction of rare diseases have 
codes in the ICD-10 coding system [16]. Still, we consid-
ered a broader catalogue of ICD-10 coded rare diseases 
than any other study we are aware of [10, 11]. The ICD-11 
coding system will provide a substantially improved rep-
resentation of rare diseases [16] than the current system. 
This will make rare diseases more visible in the coding 
system, and also, it will hopefully support and enhance 
epidemiological research regarding rare diseases. Finally, 
some interesting data were not available in our dataset: 
(i) We only had information on in-hospital deaths, but 
we did not know whether a patient died after discharge. 
In this context, we cannot rule out that some patients or 
their families preferred a different setting for end-of-life 
care than that provided in this study. And (ii) insurance 
status of patients was not available in our dataset and we 
were therefore unable to control for it in our regression 
analyses. Nevertheless, Switzerland has a highly rated 
health system with mandatory health insurance and 
nearly universal access to health care [22, 23].
The findings of this study suggest that — across a 
medically diverse adult inpatient population — patients 
with rare diseases differ from those with more common 
diseases. These differences manifest in form of worse 
clinical outcomes which also entails economic conse-
quences. We therefore advocate that patients with rare 
diseases should receive special attention in the inpa-
tient setting in order to obtain the best possible out-
comes. Since our dataset included only adult inpatients, 
future studies could investigate whether our findings 
can be replicated in datasets derived from children’s 
hospitals.
In conclusion, we analyzed a large and diverse inpatient 
cohort, we considered a broad catalogue of ICD-10 coded 
rare diseases, and we demonstrated that rare diseases are 
independently associated with worse clinical outcomes 
among inpatients. This might be the first study suggest-
ing that patients with combinations of rare diseases are 
at even higher risk, especially for in-hospital death and 
increased ICU LOS. Our results have important clinical 
implications as well as implications for healthcare utiliza-
tion and costs, and it seems critical that future efforts are 
undertaken to find ways to improve clinical outcomes of 
inpatients with rare diseases.
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